Riding the Femtech Wave: Why Progyny is a Key Stock for Investors to Track

Clara D. Flaherty

[ad_1]

The stock value of Progyny (NASDAQ: PGNY), a femtech business that specializes in fertility and household constructing benefits remedies, has relished major advancement given that its October 2019 listing – displaying that the digital women’s health business has developed into a formidable power in the wake of the Covid-19 pandemic. 

Even with latest declining price ranges sparked in no small element by a director advertising $327,285.70 in stock, Progyny was awarded an regular ‘buy’ ranking by the 10 brokerages covering the inventory. 

A lot of analysts have scrutinized PGNY shares in current months. Jefferies Economic Group begun protection on Progyny in a analysis job in December, issuing a ‘buy’ ranking and a $60 focus on selling price. While Citigroup reduce their ‘buy’ rating to a ‘neutral’ score for the inventory in November, the analysts also elevated their goal selling price for the inventory from $60 to $64

Even so, Zacks Investments and TheStreet not long ago minimize their rankings for Progyny in 2022, indicating that it may be worth offering up. JPMorgan Chase & Co also lifted their rate goal for the enterprise from $65 to $79 and gave the enterprise an ‘overweight’ ranking in an October investigate report. 

blank

As PGNY’s inventory overall performance history reveals, the stock has climbed far more than 138% next its Oct 2019 floatation, but traders are very likely to be anxious at how the leading femtech business has fared amidst the testing sector ailments of late 2021 – with inflation and fresh Covid-19 fears paving the way for mass provide-offs. 

blank

The past six months reveals that the inventory has drifted some 43.26% absent from its all-time superior benefit of $63.43, which Progyny achieved in September 2021. 

An additional contributing aspect to the stock’s latest downturn has been the a bit beneath-par Q2 revenues in 2021. While the company’s earnings have been greater than the consensus estimates around the exact time period, its inventory has drifted continually considering the fact that Q3 2021. 

Progyny also posted its steering for the total-yr 2021 with revenues approximated to access $520 million and EPS established to be about $.47 at the midpoint of their assortment. 

“Progyny’s fertility positive aspects answer incorporates differentiated benefit plan style, personalised concierge-model participant assistance expert services and a selective network of fertility professionals,” claimed Maxim Manturov, head of financial investment guidance at Flexibility Finance Europe. “The organization also provides Progyny Rx, a complete pharmacy gains answer that presents its users access to the medicines they have to have all through remedy. In addition, it offers employers with reimbursement programmes for surrogacy and adoption.”

Progyny reported its Q2 success previous month with revenues slightly below and earnings greater than the consensus estimates. The organization offered its advice for the comprehensive-calendar year 2021 with revenues estimated to be $520 million and EPS to be around $.47, at the mid-point of their selection. The blended results led to a gradual drop of above 20% in PGNY stock in the first half of August. However, the stock has found a sharp recovery more than the very last month or so, led by an greater optimism for its company potential clients.

The Increase and Increase of Femtech

The quantity of organizations in the United States that present fertility gains has experienced sustained expansion in the latest yrs as the technological innovation powering femtech grows. Positive aspects ideas can variety from infertility analysis and medicine to in vitro fertilization (IVF) and intrauterine insemination (IUI). Other, a lot more in depth programs go over egg freezing, the procurement of donor eggs or embryos, and gestational surrogacy. In one essential step for the industry, this kind of designs have developed to include members of the LGBTQ+ neighborhood, as well as one mom and dad. 

The Personnel Added benefits Survey 2020 by the Global Foundation of Worker Benefits Ideas (IFEBP) implies that 24% of corporations now cover IVF procedure, up from just 13% in 2016. The variety of companies masking egg harvesting also increased from 2% to 10% over the very same interval. Also, fertility medication climbed threefold from 8% to 24%. 

Businesses are significantly keen to adopt fertility advantages as element of their range, equity, and inclusion endeavours. By giving protection for treatment and medicine, they can not only establish improved ESG reporting and also make certain that they can attract and retain more expertise. 

This heightened fascination and consciousness of femtech can assistance to speed up development in a fledgling market that is ripe for adoption. 

Even though VC fascination has not been mainly forthcoming in new several years, the pandemic-driven rise of electronic transformation and digital wellness has aided substantial levels of publicity for women’s overall health applications. 

Progyny may have confronted important downturns in share price tag in the latest months, but the outlook for the femtech market as a entire need to be regarded as largely constructive. 

As an early trailblazer in the sector, Progyny need to be regarded as a organization that possesses a lot of upside likely. As the field grows, we can expect to see a lot more outperformance for this major femtech corporation.

[ad_2]

Resource website link

Next Post

Nan Ya to boost automotive IC substrate sales in 2022

[ad_1] Nan Ya PCB is searching to expand its automotive IC substrate product sales as a proportion of corporation earnings to over 10% in 2022, up from 7-8% in 2021, in accordance to firm sources. Nan Ya stated its revenues will see normal seasonal advancement momentum in the third quarter […]